Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Jie Li

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0605-1506; OpenAlex author ID A5100428318. Sources: OpenAlex.

Their work

Papers
18 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
47
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: 3 papers · 2018: 3 papers · 2019: 2 papers · 2020: 2 papers · 2021: 2 papers · 2022: 3 papers · 2023: none · 2024: 2 papers

Papers 18

  1. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. Co-author DOI 10.1002/cam4.7229↗
  2. Corrigendum to "2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing S… Co-author DOI 10.1016/j.canlet.2023.216602↗
  3. Corrigendum to " 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing … Co-author DOI 10.1016/j.canlet.2022.215913↗
  4. ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancer. Co-author DOI 10.18632/aging.204324↗
  5. S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study. Co-author DOI 10.3389/fonc.2022.865404↗
  6. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  7. Honokiol Suppresses Perineural Invasion of Pancreatic Cancer by Inhibiting SMAD2/3 Signaling. First author DOI 10.3389/fonc.2021.728583↗
  8. Resveratrol slows the tumourigenesis of pancreatic cancer by inhibiting NFκB activation. Co-author DOI 10.1016/j.biopha.2020.110116↗
  9. Resveratrol Ameliorates the Malignant Progression of Pancreatic Cancer by Inhibiting Hypoxia-induced Pancreatic Stellate Cell Activation. Co-author DOI 10.1177/0963689720929987↗
  10. Hypoxia-driven paracrine osteopontin/integrin αvβ3 signaling promotes pancreatic cancer cell epithelial-mesenchymal transition and cancer stem cell-like proper… First author DOI 10.1002/1878-0261.12399↗
  11. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. Co-author DOI 10.1016/j.csbj.2019.03.016↗
  12. Targeting glypican-4 overcomes 5-FU resistance and attenuates stem cell-like properties via suppression of Wnt/β-catenin pathway in pancreatic cancer cells. Co-author DOI 10.1002/jcb.27266↗
  13. Paracrine HGF/c-MET enhances the stem cell-like potential and glycolysis of pancreatic cancer cells via activation of YAP/HIF-1α. Co-author DOI 10.1016/j.yexcr.2018.07.041↗
  14. Resveratrol-Induced Downregulation of NAF-1 Enhances the Sensitivity of Pancreatic Cancer Cells to Gemcitabine via the ROS/Nrf2 Signaling Pathways. Co-author DOI 10.1155/2018/9482018↗
  15. Loss of AMPK activation promotes the invasion and metastasis of pancreatic cancer through an HSF1-dependent pathway. Co-author DOI 10.1002/1878-0261.12116↗
  16. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.prp.2017.04.024↗
  17. Metformin suppresses cancer initiation and progression in genetic mouse models of pancreatic cancer. Co-author DOI 10.1186/s12943-017-0701-0↗
  18. CacyBP/SIP enhances multidrug resistance of pancreatic cancer cells by regulation of P-gp and Bcl-2. Co-author DOI 10.1007/s10495-013-0831-9↗

Closest collaborators

The 25 strongest of 47 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 13 shared papers, 2017–2024 · strength 1.34
  2. Weikun Qian · 12 shared papers, 2017–2024 · strength 1.23
  3. Ying Xiao · 6 shared papers, 2019–2021 · strength 0.61
  4. Yangyang Yue · 4 shared papers, 2020–2024 · strength 0.61
  5. Jiguang Ma · 7 shared papers, 2017–2021 · strength 0.60
  6. Zheng Wang · 4 shared papers, 2020–2024 · strength 0.60
  7. Wanxing Duan · 7 shared papers, 2017–2021 · strength 0.59
  8. Cancan Zhou · 7 shared papers, 2017–2021 · strength 0.55
  9. Ke Chen · 7 shared papers, 2017–2021 · strength 0.53
  10. Liankang Sun · 7 shared papers, 2017–2020 · strength 0.52
  11. Junyu Cao · 7 shared papers, 2017–2019 · strength 0.52
  12. Liang Cheng · 6 shared papers, 2017–2019 · strength 0.43
  13. Zheng Wu · 3 shared papers, 2019–2024 · strength 0.42
  14. Shiqi Wu · 2 shared papers, 2022–2024 · strength 0.39
  15. Liang Han · 4 shared papers, 2018–2021 · strength 0.38
  16. Jianjun Lei · 4 shared papers, 2018–2021 · strength 0.37
  17. Tao Qin · 4 shared papers, 2018–2020 · strength 0.36
  18. Tao Qin · 3 shared papers, 2020–2021 · strength 0.32
  19. Zhengdong Jiang · 4 shared papers, 2017–2018 · strength 0.27
  20. Bin Yan · 4 shared papers, 2017–2018 · strength 0.27
  21. Shuai Wu · 1 shared paper, 2024 · strength 0.22
  22. Jiaqiang Ren · 1 shared paper, 2024 · strength 0.22
  23. Liang Han · 1 shared paper, 2024 · strength 0.22
  24. Pian Yu · 1 shared paper, 2022 · strength 0.20
  25. Cong Peng · 1 shared paper, 2022 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.